What Is BPC-157?

Overview

BPC-157 (Body Protection Compound-157, Bepecin, PL 14736) is a synthetic pentadecapeptide composed of 15 amino acids (GEPPPGKPADDAGLV), derived from a partial sequence of a larger Body Protection Compound protein naturally found in human gastric juice.[1][2]

Originally isolated by Dr. Predrag Sikiric's research group at the University of Zagreb in 1993, BPC-157 is one of the most extensively studied cytoprotective peptides in preclinical literature. It demonstrates pleiotropic effects across gastrointestinal, musculoskeletal, neurological, and vascular models.[8]

A key distinguishing feature is its exceptional stability — BPC-157 resists enzymatic degradation in human gastric juice for over 24 hours, is effective via multiple routes (oral, parenteral, topical) without requiring a carrier molecule, and has shown no lethal dose (LD1) in toxicology studies.[3][9]

The U.S. FDA placed BPC-157 on the Category 2 Bulk Drug Substances list in September 2023, citing potential immunogenicity risks and insufficient safety data for human compounding.[4] WADA explicitly banned BPC-157 under S0 (Non-approved Substances) effective January 1, 2022.[5]

Discovery and structural rationale

The "Body Protection Compound" parent protein was identified during investigations of organoprotective constituents of mammalian gastric juice in the late 1980s. The 15-residue active fragment GEPPPGKPADDAGLV preserves the proline-rich motif now believed to be central to its bioactivity: computational modeling reported in a non-peer-reviewed 2025 preprint proposes that the peptide adopts a polyproline II (PPII) helix in solution, a class of conformation recognized by the SH3 domains of Src-family kinases.[11] This proposed conformational basis, if confirmed experimentally, would distinguish BPC-157 from the disulfide- or alpha-helix-stabilized peptides typical of the regulatory-peptide literature.[1]

Research framework

Within the cytoprotective-peptide research domain, BPC-157 is most often referenced alongside Thymosin alpha-1 for parallel tissue-repair signaling, TB-500 for actin-cytoskeleton-mediated wound dynamics, and GHK-Cu for matrix-remodeling pathways. The compound is supplied here strictly as a reference standard for in vitro and animal-model investigation, and is not intended for human or veterinary use.